ClinicalTrials.gg
RecruitingNCT07504367Updated Mar 31, 2026

Large Language Models Assist in Tumor MDT

An interventional study of LLM assists in MDT report writing in Lung Cancer, Breast Cancer and Colorectal Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 2 sites in China. Open to participants aged 25 Years to 33 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
25 Years to 33 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
348th of 590
60 · median 90
Started
2026
with 91 others
No phase
214 of 850
93 open now
Primary completion
2026-12
later than 187 of 422 live
Registered
768th of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 348th largest by planned enrollment of the 590 interventional ones that give a count, is one of 92 that started in 2026, is one of 214 with no phase, reaches primary completion later than 187 of the 422 other live ones, and was the 768th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 25 Years to 33 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

Multidisciplinary teams (MDTs) represent the gold standard for personalized tumor treatment, but they are limited by medical resources and accessibility Limitation. Although large language models (LLMs) have shown promise in medical reasoning, their multidisciplinary practicality in pan-cancer MDTs has not been fully explored. In the early stage of this project, LLMs with high clinical application efficacy were identified through benchmark tests, and an open-label randomized controlled study (RCT) was conducted based on these LLMs. The research aims to explore whether AI-assisted assistance can enhance the accuracy and writing efficiency of MDT diagnosis and treatment reports. This study intends to prospectively collect the diagnosis and treatment information of 20 patients and MDT diagnosis and treatment information. It is planned to recruit 40 junior doctors. Doctors in the intervention group will use LLM to assist in the writing of MDT reports, while doctors in the control group will use traditional information retrieval methods for the writing of MDT reports. Three clinical experts ultimately used a standardized Likert scale to conduct comprehensive and multidisciplinary scoring of the MDT reports of the intervention group and the control group. This study quantitatively compared the diagnosis and treatment quality and efficiency of the MDT AI-assisted model and the traditional model to verify the application potential of large language models in assisting tumor diagnosis and treatment.

03

Conditions studied

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Liver Cancer
04

Who can participate

Ages eligible
25 Years to 33 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A junior doctor with a practicing physician qualification certificate.
  • Oncologists, surgeons, radiation oncologists, radiologists and pathologists with 3 to 5 years of clinical experience.
  • Age: 25 to 33 years old, gender not limited.
  • During the research period, one can participate for no less than 10 hours.
  • Agree to participate in this research and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Have participated in the previous diagnosis and treatment of any one of the 20 cases included in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AI-MDT

    This study was a prospective RCT, and the intervention content was an auxiliary tool for writing MDT reports. The intervention group used LLM to assist in the writing of MDT reports. The prescribed MDT medical records (excluding diagnosis and treatment opinions) were input into the LLM, and the output content could be used as a reference for the MDT report. Finally, the MDT diagnosis and treatment opinions were written under the personal judgment of the doctors.

    Other: LLM assists in MDT report writing

  • No intervention
    Trad-MDT

    The control group used traditional information retrieval methods (such as Google, literature, and textbooks) to write MDT diagnosis and treatment opinions.

Interventions

  • OtherLLM assists in MDT report writing

    This study was a prospective RCT, and the intervention content was an auxiliary tool for writing MDT reports. The intervention group used LLM to assist in the writing of MDT reports. The prescribed MDT medical records (excluding diagnosis and treatment opinions) were input into the LLM, and the output content could be used as a reference for the MDT report. Finally, the MDT diagnosis and treatment opinions were written under the personal judgment of the doctors. The control group used traditional information retrieval methods (such as Google, literature, and textbooks) to write MDT diagnosis and treatment opinions.

06

What researchers measure

Primary outcomes

  1. The overall score of the MDT report

    Clinical experts comprehensively evaluated the diagnosis and treatment opinions of different departments in the MDT report, and used the standardized Likert scale to comprehensively score the MDT reports of the intervention group and the control group (1 to 5 points, the higher the better).

    Time frame: Up to 4 weeks, complete the writing of medical opinions for all cases (n=20).

Secondary outcomes

  1. The radiation oncology score of the MDT report

    Clinical experts used a standardized Likert scale to score the radiotherapy department's diagnosis and treatment opinions reported by the MDT in the intervention group and the control group (1 to 5 points, the higher the better).

    Time frame: Up to 4 weeks, complete the writing of medical opinions for all cases (n=20).

  2. The medical oncology score of the MDT report

    Clinical experts used the standardized Likert scale to score the medical oncology diagnosis and treatment opinions reported by the MDT in the intervention group and the control group (1 to 5 points, the higher the better).

    Time frame: Up to 4 weeks, complete the writing of medical opinions for all cases (n=20).

  3. The pathology score of the MDT report

    Clinical experts used the standardized Likert scale to score the pathological diagnosis and treatment opinions reported by the MDT in the intervention group and the control group (1 to 5 points, the higher the better).

    Time frame: Up to 4 weeks, complete the writing of medical opinions for all cases (n=20).

  4. The radiology score of the MDT report

    Clinical experts used a standardized Likert scale to score the radiology diagnosis and treatment opinions reported by the MDT in the intervention group and the control group (1 to 5 points, the higher the better).

    Time frame: Up to 4 weeks, complete the writing of medical opinions for all cases (n=20).

  5. The time consumption in writing an MDT report

    The intervention group and the control group completed the MDT report for each case at all times (unit: hours).

    Time frame: Up to 4 weeks, complete the writing of medical opinions for all cases (n=20).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Requests for the individual data or study documents will be considered where the proposed use aligns with public good purposes, does not conflict with other requests, and the requestor is willing to sign a data access agreement. Contact is though the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 11 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 31, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07504367
Responsible party
Yunfang Yu (Principal Investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Mar 31, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 31, 2026

Study contacts

Yunfang Yu, PhD
Contact
yuyf9@mail.sysu.edu.cn
+8613660238987
Herui Yao, PhD
Contact
yaoherui@mail.sysu.edu.cn
+8613500018020
Yunfang Yu, PhD
study chair · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Herui Yao, PhD
study director · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion